Literature DB >> 26062980

Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.

Judi A Sgambato1, Tea Soon Park1, Diana Miller1, Leelamma M Panicker1, Ellen Sidransky1, Yu Lun1, Ola Awad1, Søren M Bentzen1, Elias T Zambidis1, Ricardo A Feldman2.   

Abstract

Gaucher disease (GD) is the most common lysosomal storage disease resulting from mutations in the lysosomal enzyme glucocerebrosidase (GCase). The hematopoietic abnormalities in GD include the presence of characteristic Gaucher macrophages that infiltrate patient tissues and cytopenias. At present, it is not clear whether these cytopenias are secondary to the pathological activity of Gaucher cells or a direct effect of GCase deficiency on hematopoietic development. To address this question, we differentiated induced pluripotent stem cells (iPSCs) derived from patients with types 1, 2, and 3 GD to CD34(+)/CD45(+)/CD43(+)/CD143(+) hematopoietic progenitor cells (HPCs) and examined their developmental potential. The formation of GD-HPCs was unaffected. However, these progenitors demonstrated a skewed lineage commitment, with increased myeloid differentiation and decreased erythroid differentiation and maturation. Interestingly, myeloid colony-formation assays revealed that GD-HPCs, but not control-HPCs, gave rise to adherent, macrophage-like cells, another indication of abnormal myelopoiesis. The extent of these hematologic abnormalities correlated with the severity of the GCase mutations. All the phenotypic abnormalities of GD-HPCs observed were reversed by incubation with recombinant GCase, indicating that these developmental defects were caused by the mutated GCase. Our results show that GCase deficiency directly impairs hematopoietic development. Additionally, our results suggest that aberrant myelopoiesis might contribute to the pathological properties of Gaucher macrophages, which are central to GD manifestations. The hematopoietic developmental defects we observed reflect hematologic abnormalities in patients with GD, demonstrating the utility of GD-iPSCs for modeling this disease. ©AlphaMed Press.

Entities:  

Keywords:  Erythropoiesis; Hematopoiesis; Hematopoietic stem cells; Induced pluripotent stem cells; Monocyte; Myeloid cells; Stem/progenitor cell

Mesh:

Year:  2015        PMID: 26062980      PMCID: PMC4511143          DOI: 10.5966/sctm.2014-0213

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  48 in total

1.  Erythrophagocytosis in Gaucher cells.

Authors:  Asaf Bitton; Joan Etzell; James P Grenert; Endi Wang
Journal:  Arch Pathol Lab Med       Date:  2004-10       Impact factor: 5.534

2.  Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis.

Authors:  Ke Chen; Jing Liu; Susanne Heck; Joel A Chasis; Xiuli An; Narla Mohandas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-28       Impact factor: 11.205

Review 3.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

4.  The majority of the in vitro erythroid expansion potential resides in CD34(-) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples.

Authors:  Emile van den Akker; Timothy J Satchwell; Stephanie Pellegrin; Geoff Daniels; Ashley M Toye
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 5.  Gaucher disease and other storage disorders.

Authors:  Gregory A Grabowski
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

6.  Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease.

Authors:  Leelamma M Panicker; Diana Miller; Tea Soon Park; Brijesh Patel; Judi L Azevedo; Ola Awad; M Athar Masood; Timothy D Veenstra; Ehud Goldin; Barbara K Stubblefield; Nahid Tayebi; Swamy K Polumuri; Stefanie N Vogel; Ellen Sidransky; Elias T Zambidis; Ricardo A Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

Review 7.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

Authors:  Kathleen S Hruska; Mary E LaMarca; C Ronald Scott; Ellen Sidransky
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

Review 8.  Gaucher disease: a comprehensive review.

Authors:  Barry E Rosenbloom; Neal J Weinreb
Journal:  Crit Rev Oncog       Date:  2013

Review 9.  Gaucher disease and myeloma.

Authors:  Robert Ayto; Derralynn A Hughes
Journal:  Crit Rev Oncog       Date:  2013

10.  Gaucher disease: clinical profile and therapeutic developments.

Authors:  Timothy M Cox
Journal:  Biologics       Date:  2010-12-06
View more
  13 in total

1.  Applications of iPSC-derived models of Gaucher disease.

Authors:  Daniel K Borger; Elma Aflaki; Ellen Sidransky
Journal:  Ann Transl Med       Date:  2015-11

2.  Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Authors:  Nelly Reihani; Jean-Benoit Arlet; Michael Dussiot; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Olivier Hermine; Caroline Le Van Kim; Melanie Franco
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

Review 3.  Gaucher disease: Progress and ongoing challenges.

Authors:  Pramod K Mistry; Grisel Lopez; Raphael Schiffmann; Norman W Barton; Neal J Weinreb; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2016-11-17       Impact factor: 4.797

Review 4.  Disease models for the development of therapies for lysosomal storage diseases.

Authors:  Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger
Journal:  Ann N Y Acad Sci       Date:  2016-05-04       Impact factor: 5.691

5.  Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells.

Authors:  Anna Speidel; Sandra Felk; Peter Reinhardt; Jared Sterneckert; Frank Gillardon
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

Review 6.  Induced pluripotent stem cell models of lysosomal storage disorders.

Authors:  Daniel K Borger; Benjamin McMahon; Tamanna Roshan Lal; Jenny Serra-Vinardell; Elma Aflaki; Ellen Sidransky
Journal:  Dis Model Mech       Date:  2017-06-01       Impact factor: 5.758

7.  Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.

Authors:  Adele Mucci; Jessica Kunkiel; Takuji Suzuki; Sebastian Brennig; Silke Glage; Mark P Kühnel; Mania Ackermann; Christine Happle; Alexandra Kuhn; Axel Schambach; Bruce C Trapnell; Gesine Hansen; Thomas Moritz; Nico Lachmann
Journal:  Stem Cell Reports       Date:  2016-07-21       Impact factor: 7.765

8.  Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation.

Authors:  Ola Awad; Leelamma M Panicker; Rania M Deranieh; Manasa P Srikanth; Robert A Brown; Antanina Voit; Tejasvi Peesay; Tea Soon Park; Elias T Zambidis; Ricardo A Feldman
Journal:  Stem Cell Reports       Date:  2017-11-30       Impact factor: 7.294

9.  Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report.

Authors:  Edit Porpaczy; Marius Mayerhoefer; Ulrike Salzer-Muhar; Ulrich Jaeger
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

10.  iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice.

Authors:  Adele Mucci; Elena Lopez-Rodriguez; Miriam Hetzel; Serena Liu; Takuji Suzuki; Christine Happle; Mania Ackermann; Henning Kempf; Roman Hillje; Jessica Kunkiel; Ewa Janosz; Sebastian Brennig; Silke Glage; Jens P Bankstahl; Sabine Dettmer; Thomas Rodt; Gudrun Gohring; Bruce Trapnell; Gesine Hansen; Cole Trapnell; Lars Knudsen; Nico Lachmann; Thomas Moritz
Journal:  Stem Cell Reports       Date:  2018-08-09       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.